董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dipal Doshi | 男 | Chief Executive Officer, President and Director | 46 | 90.55万美元 | 未持股 | 2021-08-31 |
| Carole Nuechterlein | 女 | Director | 60 | 未披露 | 未持股 | 2021-08-31 |
| Kush M. Parmar | 男 | Chairman and Director | 40 | 未披露 | 未持股 | 2021-08-31 |
| Mary Thistle | 女 | Director | 61 | 未披露 | 未持股 | 2021-08-31 |
| Todd Foley | 男 | Director | 49 | 未披露 | 未持股 | 2021-08-31 |
| John F. Crowley | 男 | Director | 54 | 3.50万美元 | 未持股 | 2021-08-31 |
| Peter S. Kim | 男 | Director | 63 | 5.52万美元 | 未持股 | 2021-08-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dipal Doshi | 男 | Chief Executive Officer, President and Director | 46 | 90.55万美元 | 未持股 | 2021-08-31 |
| Kory Wentworth | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2021-08-31 |
| Nathan J. Dowden | 男 | Chief Operating Officer | 51 | 56.15万美元 | 未持股 | 2021-08-31 |
| Nerissa C. Kreher | 女 | Chief Medical Officer | 48 | 未披露 | 未持股 | 2021-08-31 |
| Natarajan Sethuraman | 男 | Chief Scientific Officer | 59 | 57.98万美元 | 未持股 | 2021-08-31 |
董事简历
中英对照 | 中文 | 英文- Dipal Doshi
-
Dipal Doshi自2014年7月起担任公司业务规划和开发高级副总裁。加入Amicus之前， Doshi曾担任Auven Therapeutics高级副总裁，Auven Therapeutics是一家医疗私人股本和医药开发公司，他从2008年到2013年在该公司担任多个高级投资和运营职位。在Auven Therapeutics任职期间，他还担任Spirogen, Ltd. （现被AstraZeneca收购）以及ADC Therapeutics董事会观察员。从2005年到2008年他担任Catalent Pharma Solutions企业开发高级主管。 Doshi也是 Merrill Lynch一名投资银行家，Sapient Corporation战略顾问并在Eli Lilly担任多个销售和营销职位。 Doshi持有Rutgers College, Rutgers University文学学士学位以及the University of Pennsylvania沃顿商学院工商管理硕士学位。
Dipal Doshi has served as our Chief Executive Officer and President and as a member of our board of directors since August 2017. Prior to joining us, from July 2014 to August 2017 Mr. Doshi served as Chief Business Officer at Amicus Therapeutics Inc., a publicly traded biotechnology company, where he led Amicus' business and corporate development, global strategy, new product planning and commercial planning functions. Previously, from 2008 to 2013 Mr. Doshi served as Senior Vice President at Auven Therapeutics Management L.L.L.P., a healthcare private equity fund. From 2005 to 2008 Mr. Doshi held corporate development and operating roles at Catalent Pharma Solutions now Catalent, Inc.. He was also a member of Merrill Lynch's Investment Banking Group. Mr. Doshi received his B.A. from Rutgers University and his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Doshi is a Fellow of the Aspen Institute. - Dipal Doshi自2014年7月起担任公司业务规划和开发高级副总裁。加入Amicus之前， Doshi曾担任Auven Therapeutics高级副总裁，Auven Therapeutics是一家医疗私人股本和医药开发公司，他从2008年到2013年在该公司担任多个高级投资和运营职位。在Auven Therapeutics任职期间，他还担任Spirogen, Ltd. （现被AstraZeneca收购）以及ADC Therapeutics董事会观察员。从2005年到2008年他担任Catalent Pharma Solutions企业开发高级主管。 Doshi也是 Merrill Lynch一名投资银行家，Sapient Corporation战略顾问并在Eli Lilly担任多个销售和营销职位。 Doshi持有Rutgers College, Rutgers University文学学士学位以及the University of Pennsylvania沃顿商学院工商管理硕士学位。
- Dipal Doshi has served as our Chief Executive Officer and President and as a member of our board of directors since August 2017. Prior to joining us, from July 2014 to August 2017 Mr. Doshi served as Chief Business Officer at Amicus Therapeutics Inc., a publicly traded biotechnology company, where he led Amicus' business and corporate development, global strategy, new product planning and commercial planning functions. Previously, from 2008 to 2013 Mr. Doshi served as Senior Vice President at Auven Therapeutics Management L.L.L.P., a healthcare private equity fund. From 2005 to 2008 Mr. Doshi held corporate development and operating roles at Catalent Pharma Solutions now Catalent, Inc.. He was also a member of Merrill Lynch's Investment Banking Group. Mr. Doshi received his B.A. from Rutgers University and his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Doshi is a Fellow of the Aspen Institute.
- Carole Nuechterlein
-
Carole Nuechterlein，她担任我们的董事会成员（2014年10月以来）。她于2002年加入F. Hoffmann-La Roche Ltd.，目前担任the Roche Venture Fund的副董事兼主管。此前，她曾担任SangStat，Inc.的总法律顾问。她目前任职Lysosomal Therapeutics，Inc.的董事会。她持有Valparaiso University的学士学位，以及University of Michigan的法学博士学位。
Carole Nuechterlein has served as a member of our board of directors since March 2020. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd., a publicly traded healthcare company, in 2001 and currently serves as Head of the Roche Venture Fund. Ms. Nuechterlein began her legal career in private practice and later held senior legal positions, including as General Counsel to SangStat, Inc., a global pharmaceutical company, which was later acquired by Genzyme Corporation. Ms. Nuechterlein currently serves as a member of the boards of directors Aligos Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company. Previously, from March 2017 to June 2021 Ms. Nuechterlein served on the board of directors of Millendo Therapeutics, Inc., a publicly traded Biotech company and from October 2014 to May 2017 she served on the board of directors of AveXis, Inc., a publicly traded gene therapy company. She received a B.A. in English, History and Humanities from Valparaiso University and a J.D. from the University of Michigan. - Carole Nuechterlein，她担任我们的董事会成员（2014年10月以来）。她于2002年加入F. Hoffmann-La Roche Ltd.，目前担任the Roche Venture Fund的副董事兼主管。此前，她曾担任SangStat，Inc.的总法律顾问。她目前任职Lysosomal Therapeutics，Inc.的董事会。她持有Valparaiso University的学士学位，以及University of Michigan的法学博士学位。
- Carole Nuechterlein has served as a member of our board of directors since March 2020. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd., a publicly traded healthcare company, in 2001 and currently serves as Head of the Roche Venture Fund. Ms. Nuechterlein began her legal career in private practice and later held senior legal positions, including as General Counsel to SangStat, Inc., a global pharmaceutical company, which was later acquired by Genzyme Corporation. Ms. Nuechterlein currently serves as a member of the boards of directors Aligos Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company. Previously, from March 2017 to June 2021 Ms. Nuechterlein served on the board of directors of Millendo Therapeutics, Inc., a publicly traded Biotech company and from October 2014 to May 2017 she served on the board of directors of AveXis, Inc., a publicly traded gene therapy company. She received a B.A. in English, History and Humanities from Valparaiso University and a J.D. from the University of Michigan.
- Kush M. Parmar
-
Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. - Kush M. Parmar ，从2013年7月起担任Vor Biopharma Inc.董事会成员。他目前担任5AM Ventures（风险资本公司）的一般合伙人，从2010年6月起在5AM Ventures工作。此前，他是Harvard 医学院一家健康医师科学家研究所的院士，在Massachusetts General & Brigham和omen’s Hospitals 完成了临床见习；为肿瘤初创企业提供咨询服务。他还在数个私有企业董事会任职。他还是 Society of Kauffman Fellows的一位院士。持有Princeton 大学学士学位，Harvard 大学博士学位和Harvard 医学院医学博士学位。
- Kush M. Parmar has served as our co-chief executive officer and as a member of our board of directors since our inception in August 2020. Dr. Parmar is also Managing Partner at 5AM and joined in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. Dr. Parmar serves or has served as a director on the boards of Akouos, Inc. Nasdaq: AKUS, Arvinas, Inc. (Nasdaq: ARVN), Audentes Therapeutics, Inc. (which was acquired by Astellas Pharma Inc.), Entrada Therapeutics, Inc., Homology Medicines, Inc. (Nasdaq: FIXX), Rallybio Holdings, LLC, scPharmaceuticals, Inc (Nasdaq: SCPH), Vor Biopharma Inc. (Nasdaq: VOR), and Ensoma Inc. He previously served as Acting VP of Strategy and Corporate Development at Novira Therapeutics, Inc. (which was acquired by Johnson & Johnson) and served as board observer for Envoy Therapeutics Inc. (which was acquired by Takeda Pharmaceutical Company Limited), Achaogen, Inc. (Nasdaq: AKAO) and Pulmatrix, Inc. (Nasdaq: PULM). Dr. Parmar serves on the advisory boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
- Mary Thistle
-
Mary Thistle自2018年3月以来一直担任我们的董事会成员。Thistle女士自2018年1月起担任非营利生物技术组织比尔及梅林达·盖茨医学研究所的办公室主任。在此之前，她曾在基因治疗公司DimensionTherapeutics，Inc.担任高级领导职务，包括2016年至2017年担任首席运营官，2015年至2016年担任首席商务官。在加入DimensionTherapeutics，Inc.之前，她在生物制药公司CubistPharmaceuticals，Inc.工作了6年，担任过多个领导职位，包括2014年至2015年担任高级副总裁，业务开发Vice President，2012年至2013年担任业务开发高级总监，2009年至2012年担任业务开发高级总监。在此之前，她在Viacell，Inc.和PerkinElmer Inc.担任多个职位。Thistle女士担任Enterome SA的董事，这是一家位于法国巴黎的制药和诊断公司，也是Cocoon Biotech Inc.的董事。Thistle女士拥有波士顿马萨诸塞大学（University of Massachusetts，Boston）会计学士学位。
Mary Thistle has served as a member of our Board since November 2020. Ms. Thistle has served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, a non-profit biotech organization, since October 2020 and was its Chief of Staff from January 2018 until October 2020. Prior to then, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including serving as its Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Inc., she spent six years at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where she held various leadership positions, including serving as its Senior Vice President, Business Development from 2014 to 2015 Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to then, she held various positions at ViaCell, Inc. and PerkinElmer Inc. Ms. Thistle serves as a member of the boards of directors of Homology Medicines, Inc. NASDAQ: FIXX, Entrada Therapeutics, Inc. NASDAQ: TRDA and the board of directors of private companies, Enterome SA and Cocoon Biotech Inc. Ms. Thistle holds a B.S. in Accounting from the University of Massachusetts, Boston. - Mary Thistle自2018年3月以来一直担任我们的董事会成员。Thistle女士自2018年1月起担任非营利生物技术组织比尔及梅林达·盖茨医学研究所的办公室主任。在此之前，她曾在基因治疗公司DimensionTherapeutics，Inc.担任高级领导职务，包括2016年至2017年担任首席运营官，2015年至2016年担任首席商务官。在加入DimensionTherapeutics，Inc.之前，她在生物制药公司CubistPharmaceuticals，Inc.工作了6年，担任过多个领导职位，包括2014年至2015年担任高级副总裁，业务开发Vice President，2012年至2013年担任业务开发高级总监，2009年至2012年担任业务开发高级总监。在此之前，她在Viacell，Inc.和PerkinElmer Inc.担任多个职位。Thistle女士担任Enterome SA的董事，这是一家位于法国巴黎的制药和诊断公司，也是Cocoon Biotech Inc.的董事。Thistle女士拥有波士顿马萨诸塞大学（University of Massachusetts，Boston）会计学士学位。
- Mary Thistle has served as a member of our Board since November 2020. Ms. Thistle has served as Special Advisor to the Bill & Melinda Gates Medical Research Institute, a non-profit biotech organization, since October 2020 and was its Chief of Staff from January 2018 until October 2020. Prior to then, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including serving as its Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Inc., she spent six years at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where she held various leadership positions, including serving as its Senior Vice President, Business Development from 2014 to 2015 Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to then, she held various positions at ViaCell, Inc. and PerkinElmer Inc. Ms. Thistle serves as a member of the boards of directors of Homology Medicines, Inc. NASDAQ: FIXX, Entrada Therapeutics, Inc. NASDAQ: TRDA and the board of directors of private companies, Enterome SA and Cocoon Biotech Inc. Ms. Thistle holds a B.S. in Accounting from the University of Massachusetts, Boston.
- Todd Foley
-
Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Todd Foley has served as a member of our board of directors since December 2018. Mr. Foley is a Managing Director at MPM Capital LLC, a healthcare-focused venture capital firm, which he joined in 1999. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards as well as several other privately-held life sciences and pharmaceutical companies, including Repare Therapeutics Inc., Aktis Oncology, Inc., CODA Biotherapeutics Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. In addition, Mr. Foley currently serves as President of Turmeric Acquisition Corp., a recently founded special purpose acquisition company. Mr. Foley received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. - Todd Foley，2012年5月以来，他担任Chiasma, Inc.董事会成员。他是MPM Capital（风险资本公司，1999年加入）的管理董事。 1998年他在Genentech担任业务发展职务。从1994年到1997年，他在Arthur D. Little担任管理顾问职务。他目前担任 Chiasma, Inc., Iconic Therapeutics, Inc., OSS Inc., Selexys Pharmaceuticals Corporation, Valeritas Inc. 和 Rhythm Pharmaceuticals Inc.的董事会成员。他曾担任Aires Pharmaceuticals, Inc., Celladon Corporation和 Zalicus Inc.的董事会成员。他获得麻省理工学院（Massachusetts Institute of Technology）的化学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Todd Foley has served as a member of our board of directors since December 2018. Mr. Foley is a Managing Director at MPM Capital LLC, a healthcare-focused venture capital firm, which he joined in 1999. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards as well as several other privately-held life sciences and pharmaceutical companies, including Repare Therapeutics Inc., Aktis Oncology, Inc., CODA Biotherapeutics Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. In addition, Mr. Foley currently serves as President of Turmeric Acquisition Corp., a recently founded special purpose acquisition company. Mr. Foley received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
- John F. Crowley
-
John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School. - John F. Crowley，自2010年2月他为董事长兼首席执行官，自2005年1月起为首席执行官，除了从2011年4月至2011年8月期间出任执行董事长。自2004年8月，他还担任Amicus的董事，除了从2006年9月至2007年3月的期间时，他不是Amicus的职员或董事，而是在美国的海军预备役部队服役。他是Orexigen Therapeutics的总裁兼首席执行官从2003年9月至2004年12月。他Novazyme制药公司的总裁兼首席执行官从2000年3月，直到该公司于2001年9月被Genzyme公司收购；此后，他曾担任 Genzyme Therapeutics的高级副总裁直至2002年12月。他获得乔治城大学的外交学院的外交服务学士学位，圣母大学法学院的法学博士学位，和哈佛商学院的MBA学位。
- John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005 except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004 except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy Reserve. Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.
- Peter S. Kim
-
Peter S. Kim，他曾担任默克公司研究实验室（Merck Research Laboratories, Merck & Co., Inc.）的执行副总裁兼总裁（2009年11月），负责公司的研究和开发工作。他曾担任默克公司研究实验室（Merck Research Laboratories, Merck & Co., Inc.）的执行副总裁兼总裁，负责公司的研究和开发工作（2008年1月）。
Peter S. Kim has served as a member of our board of directors since December 2020. Since 2014 Dr. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and an Institute Scholar of Stanford ChEM-H. He is also the Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. Prior to his current role in academia, he was President of Merck Research Laboratories from 2003 to 2013 and oversaw development of more than 20 new medicines and vaccines, including JANUVIA, the first DPP 4 inhibitor for type 2 diabetes; GARDASIL, the first vaccine for the prevention of cervical cancer; ISENTRESS, the first HIV-1 integrase inhibitor; ZOSTAVAX, the first vaccine for the prevention of shingles; and KEYTRUDA, the first FDA approved PD-1 immune checkpoint inhibitor for the treatment of cancer. Earlier, he was Professor of Biology at MIT, Member of the Whitehead Institute and an HHMI Investigator, where he discovered a salient component of how proteins cause viral membranes to fuse with cells, designed novel compounds to stop membrane fusion by HIV-1 and pioneered efforts to create an AIDS vaccine based on similar principles. His current service includes the Medical Advisory Board of the Howard Hughes Medical Institute HHMI; the Scientific Advisory Board of the NIH Vaccine Research Center; and the Biology Department Visiting Committee of the MIT Corporation. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Engineering. Dr. Kim received a B.A. in Chemistry from Cornell University and a Ph.D. in Biochemistry from Stanford University. - Peter S. Kim，他曾担任默克公司研究实验室（Merck Research Laboratories, Merck & Co., Inc.）的执行副总裁兼总裁（2009年11月），负责公司的研究和开发工作。他曾担任默克公司研究实验室（Merck Research Laboratories, Merck & Co., Inc.）的执行副总裁兼总裁，负责公司的研究和开发工作（2008年1月）。
- Peter S. Kim has served as a member of our board of directors since December 2020. Since 2014 Dr. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and an Institute Scholar of Stanford ChEM-H. He is also the Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. Prior to his current role in academia, he was President of Merck Research Laboratories from 2003 to 2013 and oversaw development of more than 20 new medicines and vaccines, including JANUVIA, the first DPP 4 inhibitor for type 2 diabetes; GARDASIL, the first vaccine for the prevention of cervical cancer; ISENTRESS, the first HIV-1 integrase inhibitor; ZOSTAVAX, the first vaccine for the prevention of shingles; and KEYTRUDA, the first FDA approved PD-1 immune checkpoint inhibitor for the treatment of cancer. Earlier, he was Professor of Biology at MIT, Member of the Whitehead Institute and an HHMI Investigator, where he discovered a salient component of how proteins cause viral membranes to fuse with cells, designed novel compounds to stop membrane fusion by HIV-1 and pioneered efforts to create an AIDS vaccine based on similar principles. His current service includes the Medical Advisory Board of the Howard Hughes Medical Institute HHMI; the Scientific Advisory Board of the NIH Vaccine Research Center; and the Biology Department Visiting Committee of the MIT Corporation. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Engineering. Dr. Kim received a B.A. in Chemistry from Cornell University and a Ph.D. in Biochemistry from Stanford University.
高管简历
中英对照 | 中文 | 英文- Dipal Doshi
Dipal Doshi自2014年7月起担任公司业务规划和开发高级副总裁。加入Amicus之前， Doshi曾担任Auven Therapeutics高级副总裁，Auven Therapeutics是一家医疗私人股本和医药开发公司，他从2008年到2013年在该公司担任多个高级投资和运营职位。在Auven Therapeutics任职期间，他还担任Spirogen, Ltd. （现被AstraZeneca收购）以及ADC Therapeutics董事会观察员。从2005年到2008年他担任Catalent Pharma Solutions企业开发高级主管。 Doshi也是 Merrill Lynch一名投资银行家，Sapient Corporation战略顾问并在Eli Lilly担任多个销售和营销职位。 Doshi持有Rutgers College, Rutgers University文学学士学位以及the University of Pennsylvania沃顿商学院工商管理硕士学位。
Dipal Doshi has served as our Chief Executive Officer and President and as a member of our board of directors since August 2017. Prior to joining us, from July 2014 to August 2017 Mr. Doshi served as Chief Business Officer at Amicus Therapeutics Inc., a publicly traded biotechnology company, where he led Amicus' business and corporate development, global strategy, new product planning and commercial planning functions. Previously, from 2008 to 2013 Mr. Doshi served as Senior Vice President at Auven Therapeutics Management L.L.L.P., a healthcare private equity fund. From 2005 to 2008 Mr. Doshi held corporate development and operating roles at Catalent Pharma Solutions now Catalent, Inc.. He was also a member of Merrill Lynch's Investment Banking Group. Mr. Doshi received his B.A. from Rutgers University and his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Doshi is a Fellow of the Aspen Institute.- Dipal Doshi自2014年7月起担任公司业务规划和开发高级副总裁。加入Amicus之前， Doshi曾担任Auven Therapeutics高级副总裁，Auven Therapeutics是一家医疗私人股本和医药开发公司，他从2008年到2013年在该公司担任多个高级投资和运营职位。在Auven Therapeutics任职期间，他还担任Spirogen, Ltd. （现被AstraZeneca收购）以及ADC Therapeutics董事会观察员。从2005年到2008年他担任Catalent Pharma Solutions企业开发高级主管。 Doshi也是 Merrill Lynch一名投资银行家，Sapient Corporation战略顾问并在Eli Lilly担任多个销售和营销职位。 Doshi持有Rutgers College, Rutgers University文学学士学位以及the University of Pennsylvania沃顿商学院工商管理硕士学位。
- Dipal Doshi has served as our Chief Executive Officer and President and as a member of our board of directors since August 2017. Prior to joining us, from July 2014 to August 2017 Mr. Doshi served as Chief Business Officer at Amicus Therapeutics Inc., a publicly traded biotechnology company, where he led Amicus' business and corporate development, global strategy, new product planning and commercial planning functions. Previously, from 2008 to 2013 Mr. Doshi served as Senior Vice President at Auven Therapeutics Management L.L.L.P., a healthcare private equity fund. From 2005 to 2008 Mr. Doshi held corporate development and operating roles at Catalent Pharma Solutions now Catalent, Inc.. He was also a member of Merrill Lynch's Investment Banking Group. Mr. Doshi received his B.A. from Rutgers University and his M.B.A. from The Wharton School of the University of Pennsylvania. Mr. Doshi is a Fellow of the Aspen Institute.
- Kory Wentworth
Kory Wentworth自2020年11月起担任我们的首席财务官。在加入我们之前，Wentworth先生于2017年12月至2020年10月担任bluebird bio, Inc.的财务副总裁，该公司是一家上市的生物技术公司，他在该公司领导会计，税务，财务，财务运营和报告职能，并负责建立一个全球财务团队，该团队能够支持快速的业务扩展，为多个产品发布做好商业准备，股权融资和战略合作安排。在加入Bluebird Bio之前，从2008年12月至2017年12月，Wentworth先生在上市制药公司Alexion Pharmaceuticals Inc.担任越来越重要的职务，负责监督财务和会计团队，最近担任执行董事兼公司财务总监。此前，他曾任职PricewaterhouseCoopers LLP（跨国会计师事务所）（从2002年10月到2008年12月），担任多种职务，最近担任审计经理，负责保证和业务咨询实践。Wentworth先生在萨斯奎哈纳大学获得会计学学士学位，是一名注册会计师。
Kory Wentworth has served as our Chief Financial Officer since November 2020. Prior to joining us, from December 2017 to October 2020 Mr. Wentworth served as Vice President of Finance at bluebird bio, Inc., a publicly traded biotechnology company, where he led the accounting, tax, treasury, finance operations and reporting functions and was responsible for building a global finance team capable of supporting rapid operational expansion, commercial readiness for multiple product launches, equity financing and strategic collaboration arrangements. Prior to joining bluebird bio, from December 2008 to December 2017 Mr. Wentworth held positions of increasing responsibility overseeing finance and accounting teams at Alexion Pharmaceuticals Inc., a publicly traded pharmaceutical company, most recently as Executive Director and Corporate Controller. Previously, Mr. Wentworth was at PricewaterhouseCoopers LLP, a multinational accounting firm, from October 2002 to December 2008 with various titles, his most recent being Audit Manager within the Assurance and Business Advisory practice. Mr. Wentworth received his B.S. in Accounting from Susquehanna University and is a licensed Certified Public Accountant.- Kory Wentworth自2020年11月起担任我们的首席财务官。在加入我们之前，Wentworth先生于2017年12月至2020年10月担任bluebird bio, Inc.的财务副总裁，该公司是一家上市的生物技术公司，他在该公司领导会计，税务，财务，财务运营和报告职能，并负责建立一个全球财务团队，该团队能够支持快速的业务扩展，为多个产品发布做好商业准备，股权融资和战略合作安排。在加入Bluebird Bio之前，从2008年12月至2017年12月，Wentworth先生在上市制药公司Alexion Pharmaceuticals Inc.担任越来越重要的职务，负责监督财务和会计团队，最近担任执行董事兼公司财务总监。此前，他曾任职PricewaterhouseCoopers LLP（跨国会计师事务所）（从2002年10月到2008年12月），担任多种职务，最近担任审计经理，负责保证和业务咨询实践。Wentworth先生在萨斯奎哈纳大学获得会计学学士学位，是一名注册会计师。
- Kory Wentworth has served as our Chief Financial Officer since November 2020. Prior to joining us, from December 2017 to October 2020 Mr. Wentworth served as Vice President of Finance at bluebird bio, Inc., a publicly traded biotechnology company, where he led the accounting, tax, treasury, finance operations and reporting functions and was responsible for building a global finance team capable of supporting rapid operational expansion, commercial readiness for multiple product launches, equity financing and strategic collaboration arrangements. Prior to joining bluebird bio, from December 2008 to December 2017 Mr. Wentworth held positions of increasing responsibility overseeing finance and accounting teams at Alexion Pharmaceuticals Inc., a publicly traded pharmaceutical company, most recently as Executive Director and Corporate Controller. Previously, Mr. Wentworth was at PricewaterhouseCoopers LLP, a multinational accounting firm, from October 2002 to December 2008 with various titles, his most recent being Audit Manager within the Assurance and Business Advisory practice. Mr. Wentworth received his B.S. in Accounting from Susquehanna University and is a licensed Certified Public Accountant.
- Nathan J. Dowden
Nathan J.Dowden自2019年11月起担任我们的首席运营官。在加入我们之前，Dowden先生于2016年4月至2019年10月担任Rubius Therapeutics, Inc.公司发展高级副总裁，该公司是一家上市生物制药公司，他在该公司帮助开发和集成了公司的技术，资本形成和沟通策略，以支持组织从A系列到公开上市的演变，以及从发现阶段到临床阶段的状态。在加入Rubius之前，2014年1月至2016年4月，Dowden先生担任上市管理咨询公司Huron Consulting Group Inc.的董事总经理。他加入Huron，此前曾担任the Frankel Group LLC的董事总经理16年，该公司被Huron收购。Dowden先生在康涅狄格大学获得金融学士学位，并在芝加哥大学布斯商学院获得金融和营销硕士学位。
Nathan J. Dowden has served as our Chief Operating Officer since November 2019. Prior to joining us, from April 2016 to October 2019 Mr. Dowden was Senior Vice President of Corporate Development at Rubius Therapeutics, Inc., a publicly traded biopharmaceutical company, where he helped develop and integrate the company's technology, capital formation and communication strategy in support of the organization's evolution from Series A to public listing, and from discovery to clinical stage status. Prior to Rubius, from January 2014 to April 2016 Mr. Dowden served as Managing Director at the Huron Consulting Group Inc., a publicly traded management consulting firm. He joined Huron after having served as Managing Director of The Frankel Group LLC acquired by Huron for 16 years. Mr. Dowden received a B.S. in Finance from the University of Connecticut and an M.B.A. in Finance and Marketing from the University of Chicago Booth School of Business.- Nathan J.Dowden自2019年11月起担任我们的首席运营官。在加入我们之前，Dowden先生于2016年4月至2019年10月担任Rubius Therapeutics, Inc.公司发展高级副总裁，该公司是一家上市生物制药公司，他在该公司帮助开发和集成了公司的技术，资本形成和沟通策略，以支持组织从A系列到公开上市的演变，以及从发现阶段到临床阶段的状态。在加入Rubius之前，2014年1月至2016年4月，Dowden先生担任上市管理咨询公司Huron Consulting Group Inc.的董事总经理。他加入Huron，此前曾担任the Frankel Group LLC的董事总经理16年，该公司被Huron收购。Dowden先生在康涅狄格大学获得金融学士学位，并在芝加哥大学布斯商学院获得金融和营销硕士学位。
- Nathan J. Dowden has served as our Chief Operating Officer since November 2019. Prior to joining us, from April 2016 to October 2019 Mr. Dowden was Senior Vice President of Corporate Development at Rubius Therapeutics, Inc., a publicly traded biopharmaceutical company, where he helped develop and integrate the company's technology, capital formation and communication strategy in support of the organization's evolution from Series A to public listing, and from discovery to clinical stage status. Prior to Rubius, from January 2014 to April 2016 Mr. Dowden served as Managing Director at the Huron Consulting Group Inc., a publicly traded management consulting firm. He joined Huron after having served as Managing Director of The Frankel Group LLC acquired by Huron for 16 years. Mr. Dowden received a B.S. in Finance from the University of Connecticut and an M.B.A. in Finance and Marketing from the University of Chicago Booth School of Business.
- Nerissa C. Kreher
Nerissa C. Kreher曾担任Entrada Therapeutics, Inc.自2020年12月起担任首席医疗官。加入公司之前，从2019年2月到2020年10月，她担任Tiburio Therapeutics, Inc.（生物技术公司）的首席医疗官，在那里她负责临床开发、临床操作、监管和患者倡导。从2016年10月到2018年12月，她担任Avrobio, Inc.（上市临床阶段基因治疗公司）的首席医疗官，在那里她监督公司罕见疾病的临床和监管发展战略，体外慢病毒基因治疗管道项目。2015年3月至2016年7月，她曾担任Zafgen, Inc.（上市生物制药公司）的临床和医疗事务全球主管副总裁，在那里她是负责beloranib全球发展战略创建的跨职能团队的战略领导人。她目前担任Rezolute, Inc.（上市生物技术公司）的董事会成员。她持有北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）的生物学学士学位、印第安纳大学普渡大学印第安纳波利斯分校（Indiana University- purdue University Indianapolis）的临床研究硕士学位、东北大学工商管理研究生院（Northeastern University Graduate School of Business Administration）的工商管理硕士学位和东卡罗莱纳大学（East Carolina University）的医学博士学位。Kreher博士是一名委员会认证的儿科内分泌学家。
Nerissa C. Kreher serves as a member of Rezolute, Inc. Board. Since January 2025 she has been Chief Medical Officer of Alltrna. From March 2024 until December 2024, Dr. Kreher served as an interim Chief Medical Officer for Lucy Therapeutics and also was a clinical development consultant for several rare disease biotechnology companies. From December 2020 until February 2024, Dr. Kreher served as Chief Medical Officer of Entrada Therapeutics, Inc. From February 2019 to October 2020, Dr. Kreher served as Chief Medical Officer at Tiburio Therapeutics, Inc., where she was responsible for clinical development, clinical operations, regulatory and patient advocacy. From October 2016 to December 2018, Dr. Kreher served as Chief Medical Officer at Avrobio, Inc., where she oversaw clinical and regulatory development strategy for the Company's rare disease, ex vivo lentiviral gene therapy pipeline programs. From March 2015 to July 2016, Dr. Kreher served as Global Head (VP) of Clinical and Medical Affairs of Zafgen, Inc., where she was a strategic leader of a cross functional team charged with creation of global development strategy for beloranib. Dr. Kreher is a board certified pediatric endocrinologist and holds multiple degrees including her B.S. in biology from University of North Carolina at Chapel Hill, M.D. from East Carolina University, an M.S. in clinical research from Indiana University Purdue University Indianapolis, and an MBA from Northeastern University Graduate School of Biness Administration.- Nerissa C. Kreher曾担任Entrada Therapeutics, Inc.自2020年12月起担任首席医疗官。加入公司之前，从2019年2月到2020年10月，她担任Tiburio Therapeutics, Inc.（生物技术公司）的首席医疗官，在那里她负责临床开发、临床操作、监管和患者倡导。从2016年10月到2018年12月，她担任Avrobio, Inc.（上市临床阶段基因治疗公司）的首席医疗官，在那里她监督公司罕见疾病的临床和监管发展战略，体外慢病毒基因治疗管道项目。2015年3月至2016年7月，她曾担任Zafgen, Inc.（上市生物制药公司）的临床和医疗事务全球主管副总裁，在那里她是负责beloranib全球发展战略创建的跨职能团队的战略领导人。她目前担任Rezolute, Inc.（上市生物技术公司）的董事会成员。她持有北卡罗来纳大学教堂山分校（University of North Carolina at Chapel Hill）的生物学学士学位、印第安纳大学普渡大学印第安纳波利斯分校（Indiana University- purdue University Indianapolis）的临床研究硕士学位、东北大学工商管理研究生院（Northeastern University Graduate School of Business Administration）的工商管理硕士学位和东卡罗莱纳大学（East Carolina University）的医学博士学位。Kreher博士是一名委员会认证的儿科内分泌学家。
- Nerissa C. Kreher serves as a member of Rezolute, Inc. Board. Since January 2025 she has been Chief Medical Officer of Alltrna. From March 2024 until December 2024, Dr. Kreher served as an interim Chief Medical Officer for Lucy Therapeutics and also was a clinical development consultant for several rare disease biotechnology companies. From December 2020 until February 2024, Dr. Kreher served as Chief Medical Officer of Entrada Therapeutics, Inc. From February 2019 to October 2020, Dr. Kreher served as Chief Medical Officer at Tiburio Therapeutics, Inc., where she was responsible for clinical development, clinical operations, regulatory and patient advocacy. From October 2016 to December 2018, Dr. Kreher served as Chief Medical Officer at Avrobio, Inc., where she oversaw clinical and regulatory development strategy for the Company's rare disease, ex vivo lentiviral gene therapy pipeline programs. From March 2015 to July 2016, Dr. Kreher served as Global Head (VP) of Clinical and Medical Affairs of Zafgen, Inc., where she was a strategic leader of a cross functional team charged with creation of global development strategy for beloranib. Dr. Kreher is a board certified pediatric endocrinologist and holds multiple degrees including her B.S. in biology from University of North Carolina at Chapel Hill, M.D. from East Carolina University, an M.S. in clinical research from Indiana University Purdue University Indianapolis, and an MBA from Northeastern University Graduate School of Biness Administration.
- Natarajan Sethuraman
Natarajan Sethuraman自2017年9月起担任我们的首席科学官，此前曾于2016年10月至2017年8月担任顾问。在加入我们之前，从2012年8月到2016年7月，Sethuraman博士担任默克制药公司（一家上市的跨国制药公司）的执行董事兼GlycoFi网站负责人，此前从2006年8月到2012年7月担任高级董事兼GlycoFi网站负责人。在Merck，Sethuraman博士负责开发GlycoFi的差异化生物制剂Glyco工程平台，并是Merck Research Laboratories生物制剂发现领导团队的重要成员，该团队制定了所有Merck Biologics的战略和优先事项。Sethuraman博士在泰米尔纳德邦农业大学获得农业学士学位，获得理学硕士学位。印度农业研究所昆虫学和生物化学博士学位，昆虫学、分子生物学和生物化学博士学位。他在杜克大学接受博士后培训，在那里他致力于阐明在大肠杆菌中DNA复制的终止。
Natarajan Sethuraman has served as our Chief Scientific Officer since September 2017 and previously served as a consultant from October 2016 to August 2017. Prior to joining us, from August 2012 to July 2016 Dr. Sethuraman was Executive Director and the GlycoFi Site Head at Merck & Co., Inc., a publicly traded multinational pharmaceutical company, and previously served as Senior Director and GlycoFi Site Head from August 2006 to July 2012. At Merck, Dr. Sethuraman was responsible for the development of GlycoFi's glyco-engineered platform for differentiated biologics and was an integral member of the Biologics Discovery leadership team at Merck Research Laboratories which set the strategy and prioritization of all Merck biologics. Dr. Sethuraman received a B.S. in Agriculture from the Tamil Nadu Agricultural University, an M.Sc. in Entomology and Biochemistry and a Ph.D. in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute. He received his post-doctoral training at Duke University where he worked on the elucidation of the termination of DNA replication in E. coli.- Natarajan Sethuraman自2017年9月起担任我们的首席科学官，此前曾于2016年10月至2017年8月担任顾问。在加入我们之前，从2012年8月到2016年7月，Sethuraman博士担任默克制药公司（一家上市的跨国制药公司）的执行董事兼GlycoFi网站负责人，此前从2006年8月到2012年7月担任高级董事兼GlycoFi网站负责人。在Merck，Sethuraman博士负责开发GlycoFi的差异化生物制剂Glyco工程平台，并是Merck Research Laboratories生物制剂发现领导团队的重要成员，该团队制定了所有Merck Biologics的战略和优先事项。Sethuraman博士在泰米尔纳德邦农业大学获得农业学士学位，获得理学硕士学位。印度农业研究所昆虫学和生物化学博士学位，昆虫学、分子生物学和生物化学博士学位。他在杜克大学接受博士后培训，在那里他致力于阐明在大肠杆菌中DNA复制的终止。
- Natarajan Sethuraman has served as our Chief Scientific Officer since September 2017 and previously served as a consultant from October 2016 to August 2017. Prior to joining us, from August 2012 to July 2016 Dr. Sethuraman was Executive Director and the GlycoFi Site Head at Merck & Co., Inc., a publicly traded multinational pharmaceutical company, and previously served as Senior Director and GlycoFi Site Head from August 2006 to July 2012. At Merck, Dr. Sethuraman was responsible for the development of GlycoFi's glyco-engineered platform for differentiated biologics and was an integral member of the Biologics Discovery leadership team at Merck Research Laboratories which set the strategy and prioritization of all Merck biologics. Dr. Sethuraman received a B.S. in Agriculture from the Tamil Nadu Agricultural University, an M.Sc. in Entomology and Biochemistry and a Ph.D. in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute. He received his post-doctoral training at Duke University where he worked on the elucidation of the termination of DNA replication in E. coli.